Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use

Claim 2

A process for preparing a pharmaceutical composition comprising biodegradable particles, said process comprising the steps of preparing an aqueous solution of a biologically active substance and having dissolved therein a surface active agent, wherein said aqueous solution is adjusted to a pH value lower than 7 with a pharmaceutically acceptable acid; adding, with stirring, to said solution an alkyl cyanoacrylate wherein the alkyl radical has 1 to 4 carbon atoms; stirring further until substantially all of the alkyl cyanoacrylate introduced in the reaction medium has been transformed into a suspension of submicroscopic particles comprising alkyl polycyanoacrylate having a diameter less than 500 nanometers and a substantially spherical, dense, filamentous, polymeric network having dispersed therethrough the biologically active substance.

Claim 3

A process according to claim 1 wherein said aqueous solution is adjusted to a pH value in the range of 2 to 3 before the alkyl cyanoacrylate is added thereto.

Claim 4

A process according to claim 1, wherein after the suspension of submicroscopic particles has been formed, the pH value of the suspension is adjusted to a value corresponding to the pKa of the biologically active substance.

Claim 5

A process according to claim 1, wherein the biodegradable particles have a diameter of less than 200 nanometers.

Claim 6

A process according to claim 1, wherein the alkyl cyanoacrylate is methyl cyanoacrylate.

Claim 7

Process according to claim 1, wherein the aqueous solution is an aqueous colloidal solution.

Claim 8

Process according to claim 1, in which the biologically active substance is a product with antimitotic, antineoplastic, antibiotic or hormonal properties, a virus, a virus component, a bacterium component, a cell component, an antigen, an allergen or an enzyme.

Claim 9

Process for preparing a pharmaceutical composition comprising biodegradable particles, said process comprising the steps of preparing an aqueous solution of a surface active agent wherein the solution is adjusted to a pH value lower than 7 with a pharmaceutically acceptable acid; adding, with stirring, to said aqueous solution an alkyl cyanoacrylate, wherein the alkyl radical has 1 to 4 carbon atoms; stirring further until substantially all the alkyl cyanoacrylate introduced in the reaction medium has been transformed into a suspension of submicroscopic particles comprised of alkyl polycyanoacrylate; adding to the suspension of submicroscopic particles a biologically active substance; wherein the submicroscopic particles have a diameter less than 500 nanometers and a substantially spherical, dense, filamentous, polymeric network having dispersed therethrough the biologically active substance.

Claim 10

Process for preparing a pharmaceutical composition comprising biodegradable particles, said process comprising the steps of preparing an aqueous solution of a surface active agent wherein the solution is adjusted to a pH value lower than 7 with a pharmaceutically acceptable acid; adding, with stirring, to said aqueous solution an alkyl cyanoacrylate, wherein the alkyl radical has 1 to 4 carbon atoms; stirring further until substantially all the alkyl cyanoacrylate introduced in the reaction medium has been transformed into a suspension of submicroscopic particles comprised of alkyl polycyanoacrylate; adding to the suspension of submicroscopic particles a biologically active substance; wherein the submicroscopic particles have a diameter less than 500 nanometers and a substantially spherical, dense, filamentous, polymeric network having dispersed therethrough the biologically active substance.

Claim 11

A process according to claim 8, wherein said aqueous solution is adjusted to a pH value in the range of 2 to 3 before the alkyl cyanoacrylate is added thereto.

Claim 12

A process according to claim 8, wherein after the suspension of submicroscopic particles has been formed, the pH value of the suspension is adjusted to a value corresponding to the pKa of the biologically active substance.

Claim 13

A process according to claim 8, wherein the biodegradable particles have a diameter of less than 200 nanometers.

Claim 14

A process according to claim 8, wherein the alkyl cyanoacrylate is methyl cyanoacrylate.

Claim 15

A process according to claim 8, in which the biologically active substance is a product with antimitotic, antineoplastic, antibiotic or hormonal properties, a virus, a virus component, a bacterium component, a cell component, an antigen, an allergen or an enzyme.

Claim 16

Process of treating a mammal with a biologically active substance, said process comprising orally or parenterally administering to a mammal a biologically effective amount of biodegradable particles having a diameter less than 500 nanometers, said particles comprising a substantially spherical, dense, filamentous, polymeric network, wherein the polymeric network has dispersed therethrough the biologically active substance, and wherein said polymer is biodegradable in the mammal and is formed by the micellar polymerization of an alkyl cyanoacrylate, said alkyl group containing 1 to 4 carbon atoms, wherein the polymer particles are biodegraded to progressively release the biologically active substance into said mammal at a rate substantially corresponding to the rate of biodegradation of said polymer.

Claim 17

Process of treating a mammal with a biologically active substance, said process comprising orally or parenterally administering to a mammal a biologically effective amount of biodegradable particles having a diameter less than 500 nanometers, said particles comprising a substantially spherical, dense, filamentous, polymeric network, wherein the polymeric network has dispersed therethrough the biologically active substance, and wherein said polymer is biodegradable in the mammal and is formed by the micellar polymerization of an alkyl cyanoacrylate, said alkyl group containing 1 to 4 carbon atoms, wherein the polymer particles are biodegraded to progressively release the biologically active substance into said mammal at a rate substantially corresponding to the rate of biodegradation of said polymer.

Claim 18

Process according to claim 14, in which the biodegradable particles have a diameter of less than 200 nanometers.

Claim 19

Process according to claim 14 or 15, in which the alkyl cyanoacrylate is methyl cyanoacrylate.

Claim 20

Process of treating a mammal with a biologically active substance, said process comprising orally or parenterally administering to a mammal a biologically effective amount of biodegradable particles having a diameter less than 500 nanometers, said particles comprising a substantially spherical, dense, filamentous, polymeric network wherein the polymeric network has dispersed therethrough a biologically active substance, and wherein said polymer is biodegradable in the mammal and is formed by the micellar polymerization of an alkyl cyanoacrylate in an aqueous solution of a non-ionic surface active agent and at a pH less than 7, said alkyl containing 1 to 4 carbon atoms, and wherein the polymer particles are biodegraded to progressively release the biologically active substance into said mammal at a rate substantially corresponding to the rate of biodegradation of said polymer.

Claim 21

Process of treating a mammal with a biologically active substance, said process comprising orally or parenterally administering to a mammal a biologically effective amount of biodegradable particles having a diameter less than 500 nanometers, said particles comprising a substantially spherical, dense, filamentous, polymeric network wherein the polymeric network has dispersed therethrough a biologically active substance, and wherein said polymer is biodegradable in the mammal and is formed by the micellar polymerization of an alkyl cyanoacrylate in an aqueous solution of a non-ionic surface active agent and at a pH less than 7, said alkyl containing 1 to 4 carbon atoms, and wherein the polymer particles are biodegraded to progressively release the biologically active substance into said mammal at a rate substantially corresponding to the rate of biodegradation of said polymer.

Claim 22

Process according to claim 17, in which the biodegradable particles have a diameter of less than 200 nanometers.

Claim 23

Process according to claim 17 or 18, in which the alkyl cyanoacrylate is methyl cyanoacrylate.

Claim 24

A process for preparing a composition for diagnostic use comprising biodegradable particles, said process comprising the steps of preparing an aqueous solution of a diagnostic agent and having dissolved therein a surface active agent, wherein said aqueous solution is adjusted to a pH value lower than 7 with a pharmaceutically acceptable acid; adding, with stirring, to said solution an alkyl cyanoacrylate wherein the alkyl radical has 1 to 4 carbon atoms; stirring further until substantially all the alkyl cyanoacrylate introduced in the reaction medium has been transformed into a suspension of submicroscopic particles comprising alkyl polycyanoacrylate having a diameter less than 500 nanometers and a substantially spherical, dense, filamentous, polymeric network having dispersed therethrough the diagnostic agent.

Claim 25

A process for preparing a composition for diagnostic use comprising biodegradable particles, said process comprising the steps of preparing an aqueous solution of a diagnostic agent and having dissolved therein a surface active agent, wherein said aqueous solution is adjusted to a pH value lower than 7 with a pharmaceutically acceptable acid; adding, with stirring, to said solution an alkyl cyanoacrylate wherein the alkyl radical has 1 to 4 carbon atoms; stirring further until substantially all the alkyl cyanoacrylate introduced in the reaction medium has been transformed into a suspension of submicroscopic particles comprising alkyl polycyanoacrylate having a diameter less than 500 nanometers and a substantially spherical, dense, filamentous, polymeric network having dispersed therethrough the diagnostic agent.

Claim 26

A process according to claim 20, wherein said aqueous solution is adjusted to a pH value in the range of 2 to 3 before the alkyl cyanoacrylate is added thereto.

Claim 27

A process according to claim 20, wherein after the suspension of submicroscopic particles has been formed, the pH value of the suspension is adjusted to a value corresponding to the pKa of the surface active agent.

Claim 28

A process according to claim 20, wherein the biodegradable particles have a diameter of less than 200 nanometers.

Claim 29

A process according to claim 20, wherein the alkyl cyanoacrylate is methyl cyanoacrylate.

Claim 30

Process according to claim 20, wherein the aqueous solution is an aqueous colloidal solution.

Claim 31

Process according to claim 20, in which the diagnostic agent is fluorescein.

Claim 32

Process for preparing a composition for diagnostic use comprising biodegradable particles, said process comprising the steps of preparing an aqueous solution of a surface active agent wherein the solution is adjusted to a pH value lower than 7 with a pharmaceutically acceptable acid; adding, with stirring, to said aqueous solution an alkyl cyanoacrylate, wherein the alkyl radical has 1 to 4 carbon atoms; stirring further until substantially all the alkyl cyanoacrylate introduced in the reaction medium has been transformed into a suspension of submicroscopic particles comprised of alkyl polycyanoacrylate; adding to the suspension of submicroscopic particles a diagnostic agent; wherein the submicroscopic particles have a diameter less than 500 nanometers and a substantially spherical, dense, filamentous, polymeric network having dispersed therethrough the diagnostic agent.

Claim 33

Process for preparing a composition for diagnostic use comprising biodegradable particles, said process comprising the steps of preparing an aqueous solution of a surface active agent wherein the solution is adjusted to a pH value lower than 7 with a pharmaceutically acceptable acid; adding, with stirring, to said aqueous solution an alkyl cyanoacrylate, wherein the alkyl radical has 1 to 4 carbon atoms; stirring further until substantially all the alkyl cyanoacrylate introduced in the reaction medium has been transformed into a suspension of submicroscopic particles comprised of alkyl polycyanoacrylate; adding to the suspension of submicroscopic particles a diagnostic agent; wherein the submicroscopic particles have a diameter less than 500 nanometers and a substantially spherical, dense, filamentous, polymeric network having dispersed therethrough the diagnostic agent.

Claim 34

A process according to claim 27, wherein said aqueous solution is adjusted to a pH value in the range of 2 to 3 before the alkyl cyanoacrylate is added thereto.

Claim 35

A process according to claim 27, wherein after the suspension of submicroscopic particles has been formed, the pH value of the suspension is adjusted to a value corresponding to the pKa of the diagnostic agent.

Claim 36

A process according to claim 27, wherein the biodegradable particles have a diameter of less than 200 nanometers.

Claim 37

A process according to claim 27, wherein the alkyl cyanoacrylate is methyl cyanoacrylate.

Claim 38

A process according to claim 27, in which the diagnostic agent is fluorescein.

Claim 39

Process of carrying out a diagnostic test with a diagnostic agent, said process comprising adding to a biological medium to be analyzed a diagnostically sufficient amount of biodegradable particles having a diameter less than 500 nanometers, said particles comprising a substantially spherical, dense, filamentous, polymeric network, wherein the polymeric network has dispersed therethrough a diagnostic agent, and wherein said polymer is biodegradable in the medium and is formed by the micellar polymerization of an alkyl cyanoacrylate, said alkyl group containing 1 to 4 carbon atoms, and wherein the polymer particles are biodegraded in said medium to progressively release the diagnostic agent into said medium at a rate substantially corresponding to the rate of biodegradation of said polymer.

Claim 40

Process of carrying out a diagnostic test with a diagnostic agent, said process comprising adding to a biological medium to be analyzed a diagnostically sufficient amount of biodegradable particles having a diameter less than 500 nanometers, said particles comprising a substantially spherical, dense, filamentous, polymeric network, wherein the polymeric network has dispersed therethrough a diagnostic agent, and wherein said polymer is biodegradable in the medium and is formed by the micellar polymerization of an alkyl cyanoacrylate, said alkyl group containing 1 to 4 carbon atoms, and wherein the polymer particles are biodegraded in said medium to progressively release the diagnostic agent into said medium at a rate substantially corresponding to the rate of biodegradation of said polymer.

Claim 41

Process according to claim 33, in which the biodegradable particles have a diameter of less than 200 nanometers.

Claim 42

Process according to claim 33 or 34, in which the alkyl cyanoacrylate is methyl cyanoacrylate.

Claim 43

Process according to claim 33, in which the diagnostic agent is fluorescein.

Claim 44

Process of carrying out a diagnostic test with a diagnostic agent, said process comprising adding to a biological medium to be analyzed a diagnostically sufficient amount of biodegradable particles having a diameter less than 500 nanometers, said particles comprising a substantially spherical, dense, filamentous, polymeric network, wherein the polymeric network has dispersed therethrough a diagnostic agent, and wherein said polymer is biodegradable in the medium and is formed by the micellar polymerization of an alkyl cyanoacrylate in an aqueous solution of a nonionic surface active agent and at a pH less than 7, said alkyl containing 1 to 4 carbon atoms; and wherein the polymer particles are biodegraded in said medium to progressively release the diagnostic agent into said medium at a rate substantially corresponding to the rate of biodegradation of said polymer.

Claim 45

Process of carrying out a diagnostic test with a diagnostic agent, said process comprising adding to a biological medium to be analyzed a diagnostically sufficient amount of biodegradable particles having a diameter less than 500 nanometers, said particles comprising a substantially spherical, dense, filamentous, polymeric network, wherein the polymeric network has dispersed therethrough a diagnostic agent, and wherein said polymer is biodegradable in the medium and is formed by the micellar polymerization of an alkyl cyanoacrylate in an aqueous solution of a nonionic surface active agent and at a pH less than 7, said alkyl containing 1 to 4 carbon atoms; and wherein the polymer particles are biodegraded in said medium to progressively release the diagnostic agent into said medium at a rate substantially corresponding to the rate of biodegradation of said polymer.

Claim 46

Process according to claim 37, in which the biodegradable particles have a diameter of less than 200 nanometers.

Claim 47

Process according to claim 37 or 38, in which the alkyl cyanoacrylate is methyl cyanoacrylate.

Claim 48

Process according to claim 37, in which the diagnostic agent is fluorescein.

Claim 49

Process according to claim 37, in which the biodegradable particles are in the form of a mixture of nanoparticles formed from different alkyl cyanoacrylates to thereby provide nanoparticles in said mixture having different degradability kinetics in the biologically active medium.